New hope for rare cancers left behind by modern medicine

NCT ID NCT06790706

Summary

This French study is testing whether a combination of two immunotherapy drugs can help control five types of advanced rare cancers that have progressed after standard treatment. It will enroll 154 adults whose cancers have specific rare origins, such as certain mesotheliomas, thyroid cancers, and neuroendocrine tumors. The main goal is to see if the drug combination can stop the cancer from growing for at least 24 weeks, offering a new option where few exist.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • AP-HM, TIMONE Hospital, medical oncology department

    NOT_YET_RECRUITING

    Marseille, 13009, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • AP-HP, Tenon Hospital, medical oncology department

    NOT_YET_RECRUITING

    Paris, 75020, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Centre Eugène Marquis, medical oncology department

    NOT_YET_RECRUITING

    Rennes, 35042, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Centre Hospitalier Universitaire de Lille, medical oncology department

    NOT_YET_RECRUITING

    Lille, 59037, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Hospices Civils de Lyon, Medical Oncology Department, Edouard Herriot Hospital

    RECRUITING

    Lyon, 69003, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Hospices Civils de Lyon, Medical Oncology Department, Lyon SUD Hospital

    RECRUITING

    Pierre-Bénite, 69310, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Hospices Civils de Lyon, Thoracic Oncology Department, Louis Pradel Hospital

    RECRUITING

    Bron, 69500, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Insitut de Cancérologie Strasbourg Europe, medical oncology department

    NOT_YET_RECRUITING

    Strasbourg, 67200, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Institut Bergonié, medical oncology department

    NOT_YET_RECRUITING

    Bordeaux, 33076, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Institut Curie, thoracic oncology department

    NOT_YET_RECRUITING

    Paris, 75005, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Institut Gustave Roussy, medical oncology department

    NOT_YET_RECRUITING

    Villejuif, 94805, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Institut Paoli-Calmettes Marseille, medical oncology department

    NOT_YET_RECRUITING

    Marseille, 13009, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Institut Régional du Cancer de Montpellier, medical oncology department

    NOT_YET_RECRUITING

    Montpellier, 34298, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Institut de Cancerologie de l'Ouest , medical oncology department

    NOT_YET_RECRUITING

    Angers, 49055, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • ONCOPOLE Claudius Regaud, IUCT-Oncopole, medical oncology department

    NOT_YET_RECRUITING

    Toulouse, 31059, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.